614 related articles for article (PubMed ID: 25592632)
1. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
[TBL] [Abstract][Full Text] [Related]
2. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
Rajan A; Carter CA; Berman A; Cao L; Kelly RJ; Thomas A; Khozin S; Chavez AL; Bergagnini I; Scepura B; Szabo E; Lee MJ; Trepel JB; Browne SK; Rosen LB; Yu Y; Steinberg SM; Chen HX; Riely GJ; Giaccone G
Lancet Oncol; 2014 Feb; 15(2):191-200. PubMed ID: 24439931
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib in thymic carcinoma: enigmas still unresolved.
Marx A; Weis CA
Lancet Oncol; 2015 Feb; 16(2):124-5. PubMed ID: 25592633
[No Abstract] [Full Text] [Related]
4. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.
Sato J; Satouchi M; Itoh S; Okuma Y; Niho S; Mizugaki H; Murakami H; Fujisaka Y; Kozuki T; Nakamura K; Nagasaka Y; Kawasaki M; Yamada T; Machida R; Kuchiba A; Ohe Y; Yamamoto N
Lancet Oncol; 2020 Jun; 21(6):843-850. PubMed ID: 32502444
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
Remon J; Girard N; Mazieres J; Dansin E; Pichon E; Greillier L; Dubos C; Lindsay CR; Besse B
Lung Cancer; 2016 Jul; 97():99-104. PubMed ID: 27237035
[TBL] [Abstract][Full Text] [Related]
6. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial.
Conforti F; Zucali PA; Pala L; Catania C; Bagnardi V; Sala I; Della Vigna P; Perrino M; Zagami P; Corti C; Stucchi S; Barberis M; Guerini-Rocco E; Di Venosa B; De Vincenzo F; Cordua N; Santoro A; Giaccone G; De Pas TM
Lancet Oncol; 2022 Oct; 23(10):1287-1296. PubMed ID: 36096156
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.
Giaccone G; Kim C; Thompson J; McGuire C; Kallakury B; Chahine JJ; Manning M; Mogg R; Blumenschein WM; Tan MT; Subramaniam DS; Liu SV; Kaplan IM; McCutcheon JN
Lancet Oncol; 2018 Mar; 19(3):347-355. PubMed ID: 29395863
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma.
Gbolahan OB; Porter RF; Salter JT; Yiannoutsos C; Burns M; Chiorean EG; Loehrer PJ
J Thorac Oncol; 2018 Dec; 13(12):1940-1948. PubMed ID: 30121390
[TBL] [Abstract][Full Text] [Related]
9. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
Zucali PA; De Pas T; Palmieri G; Favaretto A; Chella A; Tiseo M; Caruso M; Simonelli M; Perrino M; De Vincenzo F; Toffalorio F; Damiano V; Pasello G; Garbella E; Ali M; Conforti F; Ottaviano M; Cioffi A; De Placido S; Giordano L; Bertossi M; Destro A; Di Tommaso L; Santoro A
J Clin Oncol; 2018 Feb; 36(4):342-349. PubMed ID: 29240542
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Sharma P; Retz M; Siefker-Radtke A; Baron A; Necchi A; Bedke J; Plimack ER; Vaena D; Grimm MO; Bracarda S; Arranz JÁ; Pal S; Ohyama C; Saci A; Qu X; Lambert A; Krishnan S; Azrilevich A; Galsky MD
Lancet Oncol; 2017 Mar; 18(3):312-322. PubMed ID: 28131785
[TBL] [Abstract][Full Text] [Related]
11. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
[TBL] [Abstract][Full Text] [Related]
13. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
14. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
Plimack ER; Bellmunt J; Gupta S; Berger R; Chow LQ; Juco J; Lunceford J; Saraf S; Perini RF; O'Donnell PH
Lancet Oncol; 2017 Feb; 18(2):212-220. PubMed ID: 28081914
[TBL] [Abstract][Full Text] [Related]
15. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Rini BI; Stenzl A; Zdrojowy R; Kogan M; Shkolnik M; Oudard S; Weikert S; Bracarda S; Crabb SJ; Bedke J; Ludwig J; Maurer D; Mendrzyk R; Wagner C; Mahr A; Fritsche J; Weinschenk T; Walter S; Kirner A; Singh-Jasuja H; Reinhardt C; Eisen T
Lancet Oncol; 2016 Nov; 17(11):1599-1611. PubMed ID: 27720136
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.
Ströbel P; Bargou R; Wolff A; Spitzer D; Manegold C; Dimitrakopoulou-Strauss A; Strauss L; Sauer C; Mayer F; Hohenberger P; Marx A
Br J Cancer; 2010 Jul; 103(2):196-200. PubMed ID: 20571495
[TBL] [Abstract][Full Text] [Related]
17. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.
Cho J; Kim HS; Ku BM; Choi YL; Cristescu R; Han J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Clin Oncol; 2019 Aug; 37(24):2162-2170. PubMed ID: 29906252
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
[TBL] [Abstract][Full Text] [Related]
20. Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.
Antonarelli G; Corti C; Zucali PA; Perrino M; Manglaviti S; Lo Russo G; Varano GM; Salvini P; Curigliano G; Catania C; Conforti F; De Pas T
Eur J Cancer; 2022 Oct; 174():31-36. PubMed ID: 35970033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]